This trial has been completed.

Condition alzheimer's disease
Treatment [123i]mni-672 spect
Phase phase 1
Sponsor Molecular NeuroImaging
Start date April 2013
End date March 2015
Trial size 6 participants
Trial identifier NCT01859767, MNI-672-01


This is a Phase 1, single center, open-label, non-randomized, clinical study in probable AD patients and HVs to evaluate the efficacy, safety and tolerability of a single dose of MNI-672. The underlying goal of this study is to assess MNI-672 SPECT imaging as a tool to detect ß amyloid deposition in the brain of AD research participants and young healthy male subjects. All study procedures will be conducted at Molecular NeuroImaging (MNI) in New Haven, CT. Approximately 3 patients with AD and 3 young male HVs will be recruited to participate in this study. HVs will be screened to ensure that there is no evidence of cognitive decline or significant neurological deficit.

All eligible subjects will be required to visit the study center on at least 2 occasions:

1. for one or more screening visits which should include a history and physical examination, laboratory and extensive neuro-psychological testing and MRI brain scanning. AD subjects will also undergo Amyvid PET imaging as part of the Screening Visit.

2. on one day for baseline examinations and MNI-672 administration and subsequent SPECT scanning- followed by safety measures

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
[123I]MNI-672 single photon emission tomography (SPECT)imaging
[123i]mni-672 spect MNI-672
Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.

Primary Outcomes

Number of subjects with adverse events
time frame: 2 years
Clinically significant changes in vital signs
time frame: 2 years

Secondary Outcomes

Total I-123 radioactivity in plasma
time frame: 2 years
Standard uptake values (SUV)
time frame: 2 years
Visual analysis
time frame: 2 years

Eligibility Criteria

Male or female participants at least 20 years old.

Healthy Volunteer Inclusion Criteria: - is male and is 20-30 years of age (inclusive) - has no evidence of cognitive impairment as indicated by a clinical dementia rating (CDR, [Hughes et al. 1993]) score of 0 (zero) and a score of ≥ 28 in the Mini-Mental Status Examination (MMSE, [Folstein et al. 1975]) - has MRI brain scan that has been judged as "normal (age- appropriate)" including ARWMC scale [Wahlund et al. 2001] scores supporting the lack of cerebrovascular disease (e.g., a white matter lesion score of 0 or 1 or 2 and a basal ganglia score of 0 or 1) - has no family history of AD defined by more than 1 first-degree relative Alzheimer disease subject inclusion criteria: - is male or female and is ≥ 50 of age, whereby females must be without childbearing potential (confirmed by either: age ≥ 60; or history of surgical sterilization or of hysterectomy, or last spontaneous bleeding at least 2 years prior to the study start) - presents with positive assessment for dementia of Alzheimer's type in accordance with the DSM-IV-TR and probable AD according to the NINCDS-ADRDA criteria and fulfils none of the exclusion criteria of either - does not fulfill the ICC criteria for probable DLB, the NINDS-AIREN for probable Vascular dementia, or the Neary [Neary et al. 1998] criteria for FTD - has a CDR [Hughes et al. 1993] score of 0.5, 1 or 2 - MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease (e.g., the ARWMC scale) changes limited to: a white matter lesion score of 0 or 1 or 2 and a basal ganglia score of 0 or 1) - has an Amyvid PET scan with moderate to frequent amyloid neuritic plaques based on visual interpretation - has a caregiver who is willing and able to attend study visits and perform the psychometric tests requiring the presence of a caregiver Exclusion Criteria for all subjects: - has any contraindication to MRI examination, e.g. metal implants or phobia - is scheduled for surgery and/or another invasive procedure within the time period of up to 7 days following MNI-672 application - is medically unstable and whose clinical course during the observation period is unpredictable, e.g. patients / volunteers within 14 days of myocardial infarction or stroke, unstable patients / volunteers with previous surgery (within 7 days), patients with advanced heart insufficiency (NYHA stage IV), or with acute renal failure - has a history of exposure to any radiation >15 mSv/year (e.g. occupational or radiation therapy) - is receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy) - has received anti-amyloid drug therapy - has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening, and/or any radiopharmaceutical within 10 radioactive half-lives prior to MNI-672 administration - has a brain tumor or other intracranial lesion, a disturbance of CSF circulation (e.g., normal pressure hydrocephalus) and/or a history of serious head trauma or brain surgery - has a history, physical, laboratory or imaging findings indicative of a significant neurological or psychiatric illness (for patients - other than AD) - has another disease that can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function) - has a history of alcohol or drug abuse

Additional Information

Official title An Exploratory, Open-label, Non-randomized Phase 1 Study to Evaluate the Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in Patients With Alzheimer's Disease Compared to Healthy Volunteers.
Principal investigator Danna Jennings, MD
Description To determine diagnostic efficacy of the MNI-672 SPECT scans in differentiating between patients with probable AD and HVs on the basis of neocortical tracer binding pattern, the SPECT scans will be visually assessed by a nuclear physician experienced in the field of neuro-imaging. SPECT scan findings will be classified either as abnormal (i.e., significant neocortical uptake in predefined regions) or as normal (i.e. no significant neocortical uptake in predefined regions). The visual analysis of the MNI SPECT images will be compared to the clinical diagnosis and Amyvid PET imaging results to determine the efficacy of MNI-672 as an agent to detect B-amyloid. The nuclear physician evaluating the SPECT images will be unaware of the clinical diagnosis.
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by Molecular NeuroImaging.